IL17A and psoriasis: As for psoriasis, previous studies showed that administration of MSCs by subcutaneous or intravenous injection can ameliorate skin inflammation and skin lesion on psoriasis-like animal models by suppressing IL-17 producing γδ T cells or reducing Type I Interferon production by plasmacytoid dendritic cells [22–26].